To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL

Hearticellgram-AMI

Trial Locations (10)

Unknown

Kangwon National University Hospital, Chuncheon

Chonnam National University Hospital, Gwangju

Yongin Severance Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Chungnam National University Hospital, Jungnam

Catholic University of Korea, Seoul ST. Mary's Hospital., Seoul

Korea University Medicine, Seoul

Severance Hospital, Yonsei University College of Medicine, Seoul

Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

Pharmicell Co., Ltd.

INDUSTRY